Adipokines: A link between obesity and cardiovascular disease

Journal of Cardiology

Volumn 63, Issue 4, 2014, Pages 250-259

  Nakamura, Kazuto ^a   Fuster, José J ^a   Walsh, Kenneth ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adiponectin; Cardiovascular disease; Leptin; Sfrp5; TNF

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADIPONECTIN RECEPTOR; ANGIOTENSIN II; C REACTIVE PROTEIN; CADHERIN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN RECEPTOR SUBSTRATE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; JANUS KINASE 2; LEPTIN; LEPTIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PADGEM PROTEIN; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN TYROSINE PHOSPHATASE SHP 2; RESISTIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; VASCULAR CELL ADHESION MOLECULE 1;

ADIPOCYTE; ADIPOSE TISSUE; ADIPOSE TISSUE BLOOD FLOW; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; BRAIN ISCHEMIA; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL COUNT; CELL SIZE; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DISEASE ASSOCIATION; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ERYTHROCYTE; FIBROBLAST; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INFLAMMATION; INFLAMMATORY CELL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LYMPHOCYTE; MACROPHAGE; MACROPHAGE ACTIVATION; MAST CELL; METABOLIC REGULATION; METABOLIC SYNDROME X; MICROENVIRONMENT; MONOCYTE; NONHUMAN; OBESITY; PATHOGENESIS; PHAGOCYTOSIS; REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; REVIEW; SMOOTH MUSCLE FIBER; WEIGHT REDUCTION;

ADIPONECTIN; CARDIOVASCULAR DISEASE; LEPTIN; SFRP5; TNFΑ;

ADIPOKINES; ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; CARDIOVASCULAR DISEASES; CELLULAR MICROENVIRONMENT; CHRONIC DISEASE; HOMEOSTASIS; HUMANS; INFLAMMATION; METABOLIC DISEASES; OBESITY; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84898044515     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.11.006     Document Type: Review

References (190)

1. Hedley A.A., Ogden C.L., Johnson C.L., Carroll M.D., Curtin L.R., Flegal K.M. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004, 291:2847-2850.
2. Flegal K.M., Carroll M.D., Kit B.K., Ogden C.L. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012, 307:491-497.
3. Flegal K.M., Carroll M.D., Ogden C.L., Curtin L.R. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
4. Hirsch J., Batchelor B. Adipose tissue cellularity in human obesity. Clin Endocrinol Metab 1976, 5:299-311.
5. Hausman D.B., DiGirolamo M., Bartness T.J., Hausman G.J., Martin R.J. The biology of white adipocyte proliferation. Obes Rev 2001, 2:239-254.
6. Sun K., Kusminski C.M., Scherer P.E. Adipose tissue remodeling and obesity. J Clin Invest 2011, 121:2094-2101.
7. Faust I.M., Johnson P.R., Stern J.S., Hirsch J. Diet-induced adipocyte number increase in adult rats: a new model of obesity. Am J Physiol 1978, 235:E279-E286.
8. Cartwright M.J., Tchkonia T., Kirkland J.L. Aging in adipocytes: potential impact of inherent, depot-specific mechanisms. Exp Gerontol 2007, 42:463-471.
9. Engfeldt P., Arner P. Lipolysis in human adipocytes, effects of cell size, age and of regional differences. Horm Metab Res Suppl 1988, 19:26-29.
10. Cinti S., Mitchell G., Barbatelli G., Murano I., Ceresi E., Faloia E., Wang S., Fortier M., Greenberg A.S., Obin M.S. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005, 46:2347-2355.
11. Murano I., Barbatelli G., Parisani V., Latini C., Muzzonigro G., Castellucci M., Cinti S. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res 2008, 49:1562-1568.
12. Strissel K.J., Stancheva Z., Miyoshi H., Perfield J.W., DeFuria J., Jick Z., Greenberg A.S., Obin M.S. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 2007, 56:2910-2918.
13. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
14. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A., Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821-1830.
15. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007, 117:175-184.
16. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
17. Odegaard J.I., Chawla A. Alternative macrophage activation and metabolism. Annu Rev Pathol 2011, 6:275-297.
18. Patsouris D., Li P.P., Thapar D., Chapman J., Olefsky J.M., Neels J.G. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab 2008, 8:301-309.
19. Apovian C.M., Bigornia S., Mott M., Meyers M.R., Ulloor J., Gagua M., McDonnell M., Hess D., Joseph L., Gokce N. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 2008, 28:1654-1659.
20. Feuerer M., Herrero L., Cipolletta D., Naaz A., Wong J., Nayer A., Lee J., Goldfine A.B., Benoist C., Shoelson S., Mathis D. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009, 15:930-939.
21. Winer S., Chan Y., Paltser G., Truong D., Tsui H., Bahrami J., Dorfman R., Wang Y., Zielenski J., Mastronardi F., Maezawa Y., Drucker D.J., Engleman E., Winer D., Dosch H.M. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 2009, 15:921-929.
22. Nishimura S., Manabe I., Nagasaki M., Eto K., Yamashita H., Ohsugi M., Otsu M., Hara K., Ueki K., Sugiura S., Yoshimura K., Kadowaki T., Nagai R. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009, 15:914-920.
23. Winer D.A., Winer S., Shen L., Wadia P.P., Yantha J., Paltser G., Tsui H., Wu P., Davidson M.G., Alonso M.N., Leong H.X., Glassford A., Caimol M., Kenkel J.A., Tedder T.F., et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med 2011, 17:610-617.
24. Liu J., Divoux A., Sun J., Zhang J., Clement K., Glickman J.N., Sukhova G.K., Wolters P.J., Du J., Gorgun C.Z., Doria A., Libby P., Blumberg R.S., Kahn B.B., Hotamisligil G.S., et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med 2009, 15:940-945.
25. Talukdar S., Oh da Y., Bandyopadhyay G., Li D., Xu J., McNelis J., Lu M., Li P., Yan Q., Zhu Y., Ofrecio J., Lin M., Brenner M.B., Olefsky J.M. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat Med 2012, 18:1407-1412.
26. Mansuy-Aubert V., Zhou Q.L., Xie X., Gong Z., Huang J.Y., Khan A.R., Aubert G., Candelaria K., Thomas S., Shin D.J., Booth S., Baig S.M., Bilal A., Hwang D., Zhang H., et al. Imbalance between neutrophil elastase and its inhibitor alpha1-antitrypsin in obesity alters insulin sensitivity, inflammation, and energy expenditure. Cell Metab 2013, 17:534-548.
27. Wu D., Molofsky A.B., Liang H.E., Ricardo-Gonzalez R.R., Jouihan H.A., Bando J.K., Chawla A., Locksley R.M. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 2011, 332:243-247.
28. Pasarica M., Sereda O.R., Redman L.M., Albarado D.C., Hymel D.T., Roan L.E., Rood J.C., Burk D.H., Smith S.R. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009, 58:718-725.
29. Ye J., Gao Z., Yin J., He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007, 293:E1118-E1128.
30. Pasarica M., Rood J., Ravussin E., Schwarz J.M., Smith S.R., Redman L.M. Reduced oxygenation in human obese adipose tissue is associated with impaired insulin suppression of lipolysis. J Clin Endocrinol Metab 2010, 95:4052-4055.
31. Gealekman O., Guseva N., Hartigan C., Apotheker S., Gorgoglione M., Gurav K., Tran K.V., Straubhaar J., Nicoloro S., Czech M.P., Thompson M., Perugini R.A., Corvera S. Depot-specific differences and insufficient subcutaneous adipose tissue angiogenesis in human obesity. Circulation 2011, 123:186-194.
32. Goossens G.H., Bizzarri A., Venteclef N., Essers Y., Cleutjens J.P., Konings E., Jocken J.W., Cajlakovic M., Ribitsch V., Clement K., Blaak E.E. Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation. Circulation 2011, 124:67-76.
33. Sun K., Asterholm I.W., Kusminski C.M., Bueno A.C., Wang Z.V., Pollard J.W., Brekken R.A., Scherer P.E. Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proc Natl Acad Sci U S A 2012, 109:5874-5879.
34. Elias I., Franckhauser S., Ferre T., Vila L., Tafuro S., Munoz S., Roca C., Ramos D., Pujol A., Riu E., Ruberte J., Bosch F. Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance. Diabetes 2012.
35. Sung H.K., Doh K.O., Son J.E., Park J.G., Bae Y., Choi S., Nelson S.M., Cowling R., Nagy K., Michael I.P., Koh G.Y., Adamson S.L., Pawson T., Nagy A. Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis. Cell Metab 2013, 17:61-72.
36. Corvera S., Czech M.P. Tensions rise and blood flows over dysfunctional fat. Circulation 2011, 124:13-16.
37. Jiang C., Qu A., Matsubara T., Chanturiya T., Jou W., Gavrilova O., Shah Y.M., Gonzalez F.J. Disruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed mice. Diabetes 2011, 60:2484-2495.
38. Halberg N., Khan T., Trujillo M.E., Wernstedt-Asterholm I., Attie A.D., Sherwani S., Wang Z.V., Landskroner-Eiger S., Dineen S., Magalang U.J., Brekken R.A., Scherer P.E. Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol 2009, 29:4467-4483.
39. Krishnan J., Danzer C., Simka T., Ukropec J., Walter K.M., Kumpf S., Mirtschink P., Ukropcova B., Gasperikova D., Pedrazzini T., Krek W. Dietary obesity-associated Hif1alpha activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+ system. Genes Dev 2012, 26:259-270.
40. Zhang X., Lam K.S., Ye H., Chung S.K., Zhou M., Wang Y., Xu A. Adipose tissue-specific inhibition of hypoxia-inducible factor 1{alpha} induces obesity and glucose intolerance by impeding energy expenditure in mice. J Biol Chem 2010, 285:32869-32877.
41. Nishimura S., Manabe I., Nagasaki M., Seo K., Yamashita H., Hosoya Y., Ohsugi M., Tobe K., Kadowaki T., Nagai R., Sugiura S. In vivo imaging in mice reveals local cell dynamics and inflammation in obese adipose tissue. J Clin Invest 2008, 118:710-721.
42. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
43. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J Clin Invest 2006, 116:1793-1801.
44. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., Harris T.B. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282:2131-2135.
45. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
46. Esposito K., Pontillo A., Di Palo C., Giugliano G., Masella M., Marfella R., Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289:1799-1804.
47. Samaras K., Botelho N.K., Chisholm D.J., Lord R.V. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity (Silver Spring) 2010, 18:884-889.
48. Fried S.K., Bunkin D.A., Greenberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998, 83:847-850.
49. Chatterjee T.K., Stoll L.L., Denning G.M., Harrelson A., Blomkalns A.L., Idelman G., Rothenberg F.G., Neltner B., Romig-Martin S.A., Dickson E.W., Rudich S., Weintraub N.L. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res 2009, 104:541-549.
50. Wu D., Ren Z., Pae M., Guo W., Cui X., Merrill A.H., Meydani S.N. Aging up-regulates expression of inflammatory mediators in mouse adipose tissue. J Immunol 2007, 179:4829-4839.
51. Starr M.E., Evers B.M., Saito H. Age-associated increase in cytokine production during systemic inflammation: adipose tissue as a major source of IL-6. J Gerontol A Biol Sci Med Sci 2009, 64:723-730.
52. Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011, 11:85-97.
53. Ouchi N., Kihara S., Funahashi T., Matsuzawa Y., Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003, 14:561-566.
54. Berg A.H., Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005, 96:939-949.
55. Ouchi N., Higuchi A., Ohashi K., Oshima Y., Gokce N., Shibata R., Akasaki Y., Shimono A., Walsh K. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 2010, 329:454-457.
56. Takaoka M., Nagata D., Kihara S., Shimomura I., Kimura Y., Tabata Y., Saito Y., Nagai R., Sata M. Periadventitial adipose tissue plays a critical role in vascular remodeling. Circ Res 2009, 105:906-911.
57. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
58. Kern P.A., Saghizadeh M., Ong J.M., Bosch R.J., Deem R., Simsolo R.B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995, 95:2111-2119.
59. Ziccardi P., Nappo F., Giugliano G., Esposito K., Marfella R., Cioffi M., D'Andrea F., Molinari A.M., Giugliano D. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002, 105:804-809.
60. Hivert M.F., Sullivan L.M., Fox C.S., Nathan D.M., D'Agostino R.B., Wilson P.W., Meigs J.B. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab 2008, 93:3165-3172.
61. Hotamisligil G.S., Budavari A., Murray D., Spiegelman B.M. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 1994, 94:1543-1549.
62. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389:610-614.
63. Kleinbongard P., Heusch G., Schulz R. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther 2010, 127:295-314.
64. Bruunsgaard H., Skinhoj P., Pedersen A.N., Schroll M., Pedersen B.K. Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp Immunol 2000, 121:255-260.
65. Ohta H., Wada H., Niwa T., Kirii H., Iwamoto N., Fujii H., Saito K., Sekikawa K., Seishima M. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005, 180:11-17.
66. Bergh N., Ulfhammer E., Glise K., Jern S., Karlsson L. Influence of TNF-alpha and biomechanical stress on endothelial anti- and prothrombotic genes. Biochem Biophys Res Commun 2009, 385:314-318.
67. Boesten L.S., Zadelaar A.S., van Nieuwkoop A., Gijbels M.J., de Winther M.P., Havekes L.M., van Vlijmen B.J. Tumor necrosis factor-alpha promotes atherosclerotic lesion progression in APOE*3-Leiden transgenic mice. Cardiovasc Res 2005, 66:179-185.
68. Branen L., Hovgaard L., Nitulescu M., Bengtsson E., Nilsson J., Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2004, 24:2137-2142.
69. Xiao N., Yin M., Zhang L., Qu X., Du H., Sun X., Mao L., Ren G., Zhang C., Geng Y., An L., Pan J. Tumor necrosis factor-alpha deficiency retards early fatty-streak lesion by influencing the expression of inflammatory factors in apoE-null mice. Mol Genet Metab 2009, 96:239-244.
70. Boyle J.J., Weissberg P.L., Bennett M.R. Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler Thromb Vasc Biol 2003, 23:1553-1558.
71. Goetze S., Kintscher U., Kaneshiro K., Meehan W.P., Collins A., Fleck E., Hsueh W.A., Law R.E. TNFalpha induces expression of transcription factors c-fos, Egr-1, and Ets-1 in vascular lesions through extracellular signal-regulated kinases 1/2. Atherosclerosis 2001, 159:93-101.
72. Goetze S., Xi X.P., Kawano Y., Kawano H., Fleck E., Hsueh W.A., Law R.E. TNF-alpha-induced migration of vascular smooth muscle cells is MAPK dependent. Hypertension 1999, 33:183-189.
73. Slowik M.R., De Luca L.G., Fiers W., Pober J.S. Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. Am J Pathol 1993, 143:1724-1730.
74. Kleinbongard P., Schulz R., Heusch G. TNFalpha in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail Rev 2011, 16:49-69.
75. Kadokami T., McTiernan C.F., Kubota T., Frye C.S., Feldman A.M. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. J Clin Invest 2000, 106:589-597.
76. Wajant H., Pfizenmaier K., Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003, 10:45-65.
77. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
78. Friedman J.M. Leptin, leptin receptors, and the control of body weight. Nutr Rev 1998, 56:s38-s46. discussion s54-75.
79. Oral E.A., Simha V., Ruiz E., Andewelt A., Premkumar A., Snell P., Wagner A.J., DePaoli A.M., Reitman M.L., Taylor S.I., Gorden P., Garg A. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002, 346:570-578.
80. Farooqi I.S., Matarese G., Lord G.M., Keogh J.M., Lawrence E., Agwu C., Sanna V., Jebb S.A., Perna F., Fontana S., Lechler R.I., DePaoli A.M., O'Rahilly S. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002, 110:1093-1103.
81. Bjorbak C., Lavery H.J., Bates S.H., Olson R.K., Davis S.M., Flier J.S., Myers M.G. SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J Biol Chem 2000, 275:40649-40657.
82. Dunn S.L., Bjornholm M., Bates S.H., Chen Z., Seifert M., Myers M.G. Feedback inhibition of leptin receptor/Jak2 signaling via Tyr1138 of the leptin receptor and suppressor of cytokine signaling 3. Mol Endocrinol 2005, 19:925-938.
83. Howard J.K., Cave B.J., Oksanen L.J., Tzameli I., Bjorbaek C., Flier J.S. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med 2004, 10:734-738.
84. Mori H., Hanada R., Hanada T., Aki D., Mashima R., Nishinakamura H., Torisu T., Chien K.R., Yasukawa H., Yoshimura A. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 2004, 10:739-743.
85. Myers M.G., Cowley M.A., Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008, 70:537-556.
86. Ozcan L., Ergin A.S., Lu A., Chung J., Sarkar S., Nie D., Myers M.G., Ozcan U. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab 2009, 9:35-51.
87. Grunfeld C., Zhao C., Fuller J., Pollack A., Moser A., Friedman J., Feingold K.R. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 1996, 97:2152-2157.
88. Lord G.M., Matarese G., Howard J.K., Baker R.J., Bloom S.R., Lechler R.I. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998, 394:897-901.
89. Santos-Alvarez J., Goberna R., Sanchez-Margalet V. Human leptin stimulates proliferation and activation of human circulating monocytes. Cell Immunol 1999, 194:6-11.
90. Kiguchi N., Maeda T., Kobayashi Y., Fukazawa Y., Kishioka S. Leptin enhances CC-chemokine ligand expression in cultured murine macrophage. Biochem Biophys Res Commun 2009, 384:311-315.
91. Zarkesh-Esfahani H., Pockley A.G., Wu Z., Hellewell P.G., Weetman A.P., Ross R.J. Leptin indirectly activates human neutrophils via induction of TNF-alpha. J Immunol 2004, 172:1809-1814.
92. Faggioni R., Jones-Carson J., Reed D.A., Dinarello C.A., Feingold K.R., Grunfeld C., Fantuzzi G. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc Natl Acad Sci U S A 2000, 97:2367-2372.
93. Matarese G., Di Giacomo A., Sanna V., Lord G.M., Howard J.K., Di Tuoro A., Bloom S.R., Lechler R.I., Zappacosta S., Fontana S. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol 2001, 166:5909-5916.
94. Fujimaki S., Kanda T., Fujita K., Tamura J., Kobayashi I. The significance of measuring plasma leptin in acute myocardial infarction. J Int Med Res 2001, 29:108-113.
95. Schulze P.C., Biolo A., Gopal D., Shahzad K., Balog J., Fish M., Siwik D., Colucci W.S. Dynamics in insulin resistance and plasma levels of adipokines in patients with acute decompensated and chronic stable heart failure. J Card Fail 2011, 17:1004-1011.
96. McGaffin K.R., Moravec C.S., McTiernan C.F. Leptin signaling in the failing and mechanically unloaded human heart. Circ Heart Fail 2009, 2:676-683.
97. Barouch L.A., Berkowitz D.E., Harrison R.W., O'Donnell C.P., Hare J.M. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003, 108:754-759.
98. Kanda T., Takahashi T., Kudo S., Takeda T., Tsugawa H., Takekoshi N. Leptin deficiency enhances myocardial necrosis and lethality in a murine model of viral myocarditis. Life Sci 2004, 75:1435-1447.
99. McGaffin K.R., Zou B., McTiernan C.F., O'Donnell C.P. Leptin attenuates cardiac apoptosis after chronic ischaemic injury. Cardiovasc Res 2009, 83:313-324.
100. Schiekofer S., Galasso G., Sato K., Kraus B.J., Walsh K. Impaired revascularization in a mouse model of type 2 diabetes is associated with dysregulation of a complex angiogenic-regulatory network. Arterioscler Thromb Vasc Biol 2005, 25:1603-1609.
101. Hu E., Liang P., Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996, 271:10697-10703.
102. Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y., Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221:286-289.
103. Scherer P.E., Williams S., Fogliano M., Baldini G., Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270:26746-26749.
104. Ouchi N., Kihara S., Funahashi T., Nakamura T., Nishida M., Kumada M., Okamoto Y., Ohashi K., Nagaretani H., Kishida K., Nishizawa H., Maeda N., Kobayashi H., Hiraoka H., Matsuzawa Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107:671-674.
105. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., Hotta K., Shimomura I., Nakamura T., Miyaoka K., Kuriyama H., Nishida M., Yamashita S., Okubo K., Matsubara K., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
106. Li S., Shin H.J., Ding E.L., van Dam R.M. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009, 302:179-188.
107. Fruebis J., Tsao T.S., Javorschi S., Ebbets-Reed D., Erickson M.R., Yen F.T., Bihain B.E., Lodish H.F. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001, 98:2005-2010.
108. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., Furuyama N., Kondo H., Takahashi M., Arita Y., Komuro R., Ouchi N., Kihara S., Tochino Y., Okutomi K., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731-737.
109. Nawrocki A.R., Rajala M.W., Tomas E., Pajvani U.B., Saha A.K., Trumbauer M.E., Pang Z., Chen A.S., Ruderman N.B., Chen H., Rossetti L., Scherer P.E. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2006, 281:2654-2660.
110. Kim J.Y., van de Wall E., Laplante M., Azzara A., Trujillo M.E., Hofmann S.M., Schraw T., Durand J.L., Li H., Li G., Jelicks L.A., Mehler M.F., Hui D.Y., Deshaies Y., Shulman G.I., et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007, 117:2621-2637.
111. Tomas E., Tsao T.S., Saha A.K., Murrey H.E., Zhang Cc C., Itani S.I., Lodish H.F., Ruderman N.B. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A 2002, 99:16309-16313.
112. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295.
113. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., Sugiyama T., Miyagishi M., Hara K., Tsunoda M., Murakami K., Ohteki T., Uchida S., Takekawa S., Waki H., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
114. Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M., Okada-Iwabu M., Kawamoto S., Kubota N., Kubota T., Ito Y., Kamon J., Tsuchida A., Kumagai K., Kozono H., et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007, 13:332-339.
115. (2+) and AMPK/SIRT1. Nature 2010, 464:1313-1319.
116. Garitaonandia I., Smith J.L., Kupchak B.R., Lyons T.J. Adiponectin identified as an agonist for PAQR3/RKTG using a yeast-based assay system. J Recept Signal Transduct Res 2009, 29:67-73.
117. Yamauchi T., Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab 2013, 17:185-196.
118. Hug C., Wang J., Ahmad N.S., Bogan J.S., Tsao T.S., Lodish H.F. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A 2004, 101:10308-10313.
119. Ohashi K., Parker J.L., Ouchi N., Higuchi A., Vita J.A., Gokce N., Pedersen A.A., Kalthoff C., Tullin S., Sams A., Summer R., Walsh K. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 2010, 285:6153-6160.
120. Ouchi N., Kihara S., Arita Y., Nishida M., Matsuyama A., Okamoto Y., Ishigami M., Kuriyama H., Kishida K., Nishizawa H., Hotta K., Muraguchi M., Ohmoto Y., Yamashita S., Funahashi T. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-1063.
121. Yamaguchi N., Argueta J.G., Masuhiro Y., Kagishita M., Nonaka K., Saito T., Hanazawa S., Yamashita Y. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett 2005, 579:6821-6826.
122. Kumada M., Kihara S., Ouchi N., Kobayashi H., Okamoto Y., Ohashi K., Maeda K., Nagaretani H., Kishida K., Maeda N., Nagasawa A., Funahashi T., Matsuzawa Y. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004, 109:2046-2049.
123. Takemura Y., Ouchi N., Shibata R., Aprahamian T., Kirber M.T., Summer R.S., Kihara S., Walsh K. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 2007, 117:375-386.
124. Savill J., Dransfield I., Gregory C., Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002, 2:965-975.
125. Fantuzzi G. Adiponectin in inflammatory and immune-mediated diseases. Cytokine 2013, 64:1-10.
126. Parker J., Menn-Josephy H., Laskow B., Takemura Y., Aprahamian T. Modulation of lupus phenotype by adiponectin deficiency in autoimmune mouse models. J Clin Immunol 2011, 31:167-173.
127. Aprahamian T., Bonegio R.G., Richez C., Yasuda K., Chiang L.K., Sato K., Walsh K., Rifkin I.R. The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. J Immunol 2009, 182:340-346.
128. Sattar N., Wannamethee G., Sarwar N., Tchernova J., Cherry L., Wallace A.M., Danesh J., Whincup P.H. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006, 114:623-629.
129. Iwashima Y., Katsuya T., Ishikawa K., Ouchi N., Ohishi M., Sugimoto K., Fu Y., Motone M., Yamamoto K., Matsuo A., Ohashi K., Kihara S., Funahashi T., Rakugi H., Matsuzawa Y., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004, 43:1318-1323.
130. Hong S.J., Park C.G., Seo H.S., Oh D.J., Ro Y.M. Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press 2004, 13:236-242.
131. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
132. Shibata R., Ouchi N., Kihara S., Sato K., Funahashi T., Walsh K. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem 2004, 279:28670-28674.
133. Kondo M., Shibata R., Miura R., Shimano M., Kondo K., Li P., Ohashi T., Kihara S., Maeda N., Walsh K., Ouchi N., Murohara T. Caloric restriction stimulates revascularization in response to ischemia via adiponectin-mediated activation of endothelial nitric-oxide synthase. J Biol Chem 2009, 284:1718-1724.
134. Nishimura M., Izumiya Y., Higuchi A., Shibata R., Qiu J., Kudo C., Shin H.K., Moskowitz M.A., Ouchi N. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 2008, 117:216-223.
135. Matsuda M., Shimomura I., Sata M., Arita Y., Nishida M., Maeda N., Kumada M., Okamoto Y., Nagaretani H., Nishizawa H., Kishida K., Komuro R., Ouchi N., Kihara S., Nagai R., et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002, 277:37487-37491.
136. Ohashi K., Kihara S., Ouchi N., Kumada M., Fujita K., Hiuge A., Hibuse T., Ryo M., Nishizawa H., Maeda N., Maeda K., Shibata R., Walsh K., Funahashi T., Shimomura I. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006, 47:1108-1116.
137. Li R., Wang W.Q., Zhang H., Yang X., Fan Q., Christopher T.A., Lopez B.L., Tao L., Goldstein B.J., Gao F., Ma X.L. Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity. Am J Physiol Endocrinol Metab 2007, 293:E1703-E1708.
138. Okamoto Y., Folco E.J., Minami M., Wara A.K., Feinberg M.W., Sukhova G.K., Colvin R.A., Kihara S., Funahashi T., Luster A.D., Libby P. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res 2008, 102:218-225.
139. Okamoto Y., Kihara S., Ouchi N., Nishida M., Arita Y., Kumada M., Ohashi K., Sakai N., Shimomura I., Kobayashi H., Terasaka N., Inaba T., Funahashi T., Matsuzawa Y. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 106:2767-2770.
140. Yamauchi T., Kamon J., Waki H., Imai Y., Shimozawa N., Hioki K., Uchida S., Ito Y., Takakuwa K., Matsui J., Takata M., Eto K., Terauchi Y., Komeda K., Tsunoda M., et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003, 278:2461-2468.
141. Nawrocki A.R., Hofmann S.M., Teupser D., Basford J.E., Durand J.L., Jelicks L.A., Woo C.W., Kuriakose G., Factor S.M., Tanowitz H.B., Hui D.Y., Tabas I., Scherer P.E. Lack of association between adiponectin levels and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2010, 30:1159-1165.
142. Ouchi N., Kobayashi H., Kihara S., Kumada M., Sato K., Inoue T., Funahashi T., Walsh K. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004, 279:1304-1309.
143. Chen H., Montagnani M., Funahashi T., Shimomura I., Quon M.J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003, 278:45021-45026.
144. Kobayashi H., Ouchi N., Kihara S., Walsh K., Kumada M., Abe Y., Funahashi T., Matsuzawa Y. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004, 94:e27-e31.
145. Ohashi K., Ouchi N., Sato K., Higuchi A., Ishikawa T.O., Herschman H.R., Kihara S., Walsh K. Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2-dependent mechanism. Mol Cell Biol 2009, 29:3487-3499.
146. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Okamoto Y., Hotta K., Nishida M., Takahashi M., Nakamura T., Yamashita S., Funahashi T., Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473-2476.
147. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., Hotta K., Nishida M., Takahashi M., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Funahashi T., Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
148. Arita Y., Kihara S., Ouchi N., Maeda K., Kuriyama H., Okamoto Y., Kumada M., Hotta K., Nishida M., Takahashi M., Nakamura T., Shimomura I., Muraguchi M., Ohmoto Y., Funahashi T., et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002, 105:2893-2898.
149. Ding M., Xie Y., Wagner R.J., Jin Y., Carrao A.C., Liu L.S., Guzman A.K., Powell R.J., Hwa J., Rzucidlo E.M., Martin K.A. Adiponectin induces vascular smooth muscle cell differentiation via repression of mammalian target of rapamycin complex 1 and FoxO4. Arterioscler Thromb Vasc Biol 2011, 31:1403-1410.
150. Liao Y., Takashima S., Maeda N., Ouchi N., Komamura K., Shimomura I., Hori M., Matsuzawa Y., Funahashi T., Kitakaze M. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 2005, 67:705-713.
151. Tao L., Gao E., Jiao X., Yuan Y., Li S., Christopher T.A., Lopez B.L., Koch W., Chan L., Goldstein B.J., Ma X.L. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007, 115:1408-1416.
152. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., Funahashi T., Ouchi N., Walsh K. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005, 11:1096-1103.
153. Sam F., Duhaney T.A., Sato K., Wilson R.M., Ohashi K., Sono-Romanelli S., Higuchi A., De Silva D.S., Qin F., Walsh K., Ouchi N. Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure. Endocrinology 2010, 151:322-331.
154. Shibata R., Izumiya Y., Sato K., Papanicolaou K., Kihara S., Colucci W.S., Sam F., Ouchi N., Walsh K. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J Mol Cell Cardiol 2007, 42:1065-1074.
155. Denzel M.S., Scimia M.C., Zumstein P.M., Walsh K., Ruiz-Lozano P., Ranscht B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 2010, 120:4342-4352.
156. Parker-Duffen J.L., Nakamura K., Silver M., Kikuchi R., Tigges U., Yoshida S., Denzel M.S., Ranscht B., Walsh K. T-cadherin is essential for adiponectin-mediated revascularization. J Biol Chem 2013, 288:24886-24897.
157. Ivanov D., Philippova M., Antropova J., Gubaeva F., Iljinskaya O., Tararak E., Bochkov V., Erne P., Resink T., Tkachuk V. Expression of cell adhesion molecule T-cadherin in the human vasculature. Histochem Cell Biol 2001, 115:231-242.
158. Hebbard L.W., Garlatti M., Young L.J., Cardiff R.D., Oshima R.G., Ranscht B. T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res 2008, 68:1407-1416.
159. Sabio G., Das M., Mora A., Zhang Z., Jun J.Y., Ko H.J., Barrett T., Kim J.K., Davis R.J. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008, 322:1539-1543.
160. Solinas G., Vilcu C., Neels J.G., Bandyopadhyay G.K., Luo J.L., Naugler W., Grivennikov S., Wynshaw-Boris A., Scadeng M., Olefsky J.M., Karin M. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab 2007, 6:386-397.
161. Vallerie S.N., Furuhashi M., Fucho R., Hotamisligil G.S. A predominant role for parenchymal c-Jun amino terminal kinase (JNK) in the regulation of systemic insulin sensitivity. PLoS One 2008, 3:e3151.
162. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., Karin M., Hotamisligil G.S. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
163. Pereira C., Schaer D.J., Bachli E.B., Kurrer M.O., Schoedon G. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol 2008, 28:504-510.
164. Blumenthal A., Ehlers S., Lauber J., Buer J., Lange C., Goldmann T., Heine H., Brandt E., Reiling N. The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. Blood 2006, 108:965-973.
165. Kim J., Kim J., Kim D.W., Ha Y., Ihm M.H., Kim H., Song K., Lee I. Wnt5a induces endothelial inflammation via beta-catenin-independent signaling. J Immunol 2010, 185:1274-1282.
166. Stefater J.A., Lewkowich I., Rao S., Mariggi G., Carpenter A.C., Burr A.R., Fan J., Ajima R., Molkentin J.D., Williams B.O., Wills-Karp M., Pollard J.W., Yamaguchi T., Ferrara N., Gerhardt H., et al. Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Nature 2011, 474:511-515.
167. Christman M.A., Goetz D.J., Dickerson E., McCall K.D., Lewis C.J., Benencia F., Silver M.J., Kohn L.D., Malgor R. Wnt5a is expressed in murine and human atherosclerotic lesions. Am J Physiol Heart Circ Physiol 2008, 294:H2864-H2870.
168. Burnett M.S., Lee C.W., Kinnaird T.D., Stabile E., Durrani S., Dullum M.K., Devaney J.M., Fishman C., Stamou S., Canos D., Zbinden S., Clavijo L.C., Jang G.J., Andrews J.A., Zhu J., et al. The potential role of resistin in atherogenesis. Atherosclerosis 2005, 182:241-248.
169. Kawanami D., Maemura K., Takeda N., Harada T., Nojiri T., Imai Y., Manabe I., Utsunomiya K., Nagai R. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004, 314:415-419.
170. Verma S., Li S.H., Wang C.H., Fedak P.W., Li R.K., Weisel R.D., Mickle D.A. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003, 108:736-740.
171. Robertson S.A., Rae C.J., Graham A. Induction of angiogenesis by murine resistin: putative role of PI3-kinase and NO-dependent pathways. Regul Pept 2009, 152:41-47.
172. Mu H., Ohashi R., Yan S., Chai H., Yang H., Lin P., Yao Q., Chen C. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 2006, 70:146-157.
173. Weikert C., Westphal S., Berger K., Dierkes J., Mohlig M., Spranger J., Rimm E.B., Willich S.N., Boeing H., Pischon T. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab 2008, 93:2647-2653.
174. Rajpathak S.N., Kaplan R.C., Wassertheil-Smoller S., Cushman M., Rohan T.E., McGinn A.P., Wang T., Strickler H.D., Scherer P.E., Mackey R., Curb D., Ho G.Y. Resistin, but not adiponectin and leptin, is associated with the risk of ischemic stroke among postmenopausal women: results from the Women's Health Initiative. Stroke 2011, 42:1813-1820.
175. Frankel D.S., Vasan R.S., D'Agostino R.B., Benjamin E.J., Levy D., Wang T.J., Meigs J.B. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 2009, 53:754-762.
176. Cho Y., Lee S.E., Lee H.C., Hur J., Lee S., Youn S.W., Lee J., Lee H.J., Lee T.K., Park J., Hwang S.J., Kwon Y.W., Cho H.J., Oh B.H., Park Y.B., et al. Adipokine resistin is a key player to modulate monocytes, endothelial cells, and smooth muscle cells, leading to progression of atherosclerosis in rabbit carotid artery. J Am Coll Cardiol 2011, 57:99-109.
177. Cabre A., Lazaro I., Girona J., Manzanares J., Marimon F., Plana N., Heras M., Masana L. Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes. J Intern Med 2007, 262:496-503.
178. Ingelsson E., Lind L. Circulating retinol-binding protein 4 and subclinical cardiovascular disease in the elderly. Diabetes Care 2009, 32:733-735.
179. Ingelsson E., Sundstrom J., Melhus H., Michaelsson K., Berne C., Vasan R.S., Riserus U., Blomhoff R., Lind L., Arnlov J. Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. Atherosclerosis 2009, 206:239-244.
180. Mohapatra J., Sharma M., Acharya A., Pandya G., Chatterjee A., Balaraman R., Jain M.R. Retinol-binding protein 4: a possible role in cardiovascular complications. Br J Pharmacol 2011, 164:1939-1948.
181. Norseen J., Hosooka T., Hammarstedt A., Yore M.M., Kant S., Aryal P., Kiernan U.A., Phillips D.A., Maruyama H., Kraus B.J., Usheva A., Davis R.J., Smith U., Kahn B.B. Retinol-binding protein 4 inhibits insulin signaling in adipocytes by inducing proinflammatory cytokines in macrophages through a c-Jun N-terminal kinase- and toll-like receptor 4-dependent and retinol-independent mechanism. Mol Cell Biol 2012, 32:2010-2019.
182. Yan Q.W., Yang Q., Mody N., Graham T.E., Hsu C.H., Xu Z., Houstis N.E., Kahn B.B., Rosen E.D. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007, 56:2533-2540.
183. Zhang J., Wu Y., Zhang Y., Leroith D., Bernlohr D.A., Chen X. The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol Endocrinol 2008, 22:1416-1426.
184. Tabata M., Kadomatsu T., Fukuhara S., Miyata K., Ito Y., Endo M., Urano T., Zhu H.J., Tsukano H., Tazume H., Kaikita K., Miyashita K., Iwawaki T., Shimabukuro M., Sakaguchi K., et al. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell Metab 2009, 10:178-188.
185. Elhage R., Clamens S., Besnard S., Mallat Z., Tedgui A., Arnal J., Maret A., Bayard F. Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein E-deficient mice. Atherosclerosis 2001, 156:315-320.
186. Huber S.A., Sakkinen P., Conze D., Hardin N., Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1999, 19:2364-2367.
187. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
188. Enomoto T., Ohashi K., Shibata R., Higuchi A., Maruyama S., Izumiya Y., Walsh K., Murohara T., Ouchi N. Adipolin/C1qdc2/CTRP12 protein functions as an adipokine that improves glucose metabolism. J Biol Chem 2011, 286:34552-34558.
189. Yamawaki H., Kuramoto J., Kameshima S., Usui T., Okada M., Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011, 408:339-343.
190. Maruyama S., Shibata R., Kikuchi R., Izumiya Y., Rokutanda T., Araki S., Kataoka Y., Ohashi K., Daida H., Kihara S., Ogawa H., Murohara T., Ouchi N. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J Biol Chem 2012, 287:408-417.